Amgen Inc

Amgen Inc. (formerly known as Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Amgen Inc is one of the world’s largest independent biotechnology companies and has a rich history that dates to 1980 when it was founded.

The word AMGen is derived from the company’s original name, Applied Molecular Genetics, and became the official name of the group in 1983. Amgen Inc oversees a high-value product portfolio which include discovering, developing, manufacturing, and delivering human therapeutics worldwide.

Focused on molecular biology and biochemistry, Amgen Inc’s goal is to provide a healthcare business based on recombinant DNA technology. Amgen Inc focuses on the treatment of inflammation, oncology/haematology, bone health, cardiovascular disease, nephrology and neuroscience areas and its products treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; reducing the chance of infection due a low white blood cell count in patients with cancer; treating postmenopausal women with osteoporosis and many more.

Amgen Inc. serves several healthcare providers, clinics, dialysis centres, hospitals, and pharmacies and distributes its products through pharmaceutical wholesale distributors or direct-to-consumer channels. The company’s first CEO was co-founder George B. Rathmann, followed by Gordon M. Binder in 1988, and Kevin W. Sharer in 2000. Robert A. Bradway became Amgen’s president and CEO in May 2012.

Amgen Inc acquired Dezima Pharma in 2015, and in 2016 purchased the rights to Boehringer Ingelheims Phase I bispecific T-cell engager compound. Cash returned to shareholders totalled a record $6.5 billion through dividends and share repurchases in 2017 and in 2018 Amgen Inc was ranked 123 on the Fortune 500 list of the largest United States corporations by revenue.

In 2019 Amgen Inc. acquired Nuevolution AB for $166.8 million to enhance its drug discovery capabilities, the Otezla drug programme from Celgene for $13.4 billion, and a 20.5% stake in the Beijing-based BeiGene for $2.7 billion. In March 2025, Amgen Inc acquired Five Prime Therapeutics and its lead candidate, Bemarituzumab, for $1.9 billion and Rodeo Therapeutics for up to $720 million.

Today, Amgen Inc is truly one of the most valuable healthcare providers and drug manufacturers in the world with a market capitalization of US$142.04 Billion recorded in July 2025. In 2025 the total staff compliment for Amgen Inc reported was approximately 24,300.

After facing declining sales of mature products in 2019, the company has returned to growth in 2025, with a 12% increase in product sales in the third quarter of the year. Otezla, an immunology drug acquired from Celgene, and Amgen’s own portfolio of newer drugs, have become important growth drivers.

Enbrel, the company’s top-selling product, received a new lease on commercial life when a federal appellate decision validated the covering patent, giving it an extension of marketing exclusivity through to 2029. Amgen Inc may also benefit from the launch of new products and from a collaboration agreement with Chinese biotech company BeiGene.

Despite the Covid pandemic, Amgen Inc’s 3Q20 earnings were better than expected and its Adjusted EPS rose 19% to $4.37. Worldwide product volume grew 18% (from 13% in 2Q20) with growth contributors including Otezla, Repatha, Mvasi and Kanjinti.

Amgen’s biosimilar sales was $478 million, growing 176%. The lower volume of physician-patient interactions through the pandemic has affected prescription volumes for certain drugs and Amgen Inc’s financials.

Amgen Inc trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol AMGN. Amgen Inc forms part of the NASDAQ-100 component and GLOBAL SELECT MARKET. An analysis on the market performance for the first quarter of 2025 indicated a total revenue of US$ 25 164 000 000 along with a gross profit of $ 19 028 000 000 and EBITDA of 12 716 000 000.

During the first three quarters of 2025, Amgen Inc posted a return to growth, earning $4.37 per share on $6.42 billion in sales for the third quarter. Earnings advanced 19% and sales rose 12%. Both measures accelerated year over year. Third-quarter revenue from Amgen’s biggest drug, an inflammatory medicine called Enbrel, fell 3% to roughly $1.33 billion. The company’s biggest growth stemmed from migraine treatment Repatha which saw sales rise 59% to $105 million.

For the fourth quarter, analysts expect Amgen to report earnings of $3.41 per share on $6.59 billion in sales. Profit would decline 6% and sales would gain 6%. Although Amgen Inc is solidly profitable, quarterly earnings growth has generally stayed below 25% since 2007.

On April 2, Amgen Inc stock popped almost 6% after the biotech company announced a partnership with Adaptive Biotechnologies (ADPT) to develop coronavirus treatments or preventative drugs. Adaptive will screen patients who have recovered from Covid-19. From there, the biotech company expects to be able to identify antibodies in common that could neutralise the SARS-CoV-2 virus. After that Amgen Inc will run tests to determine which antibodies could prove to be the most effective in coronavirus treatment for patients.

The need for a coronavirus treatment keeps deepening as Europe and most U.S. states have seen a resurgence in Covid-19 cases. Amgen Inc also has a collaboration deal with China’s BeiGene (BGNE) to develop cancer drugs. BeiGene will develop and commercialize the drugs in China. In exchange, Amgen took a $2.7 billion stake in the company. BeiGene will also sell three other Amgen drugs in that country.

The Amgen Inc stock price is currently around 247.630 USD and is expected to be able to go up to 267.805 USD in one year. It may be profitable to invest in Amgen Inc stock since the long-term earning potential is +8.15% in one year.

The Amgen Inc future stock price can be worth 360.585 USD in five years (2026) and there is no fear that the Amgen Inc stock price would crash. Having access to credible news sources related to Amgen’s direct competition is more important than ever and may enhance an investor’s ability to predict Amgen’s future price movements.

Getting to know how Amgen Inc rivals react to changing market sentiment, related social signals, and mainstream news is an effective way to find investing opportunities and time the market effectively. A good summary table can summarise the essential lagging indicators that can help an investor analyse how Amgen Inc may potentially react to the hype associated with one of its peers. Data from the analysis should be weighed against forecasted performance during this pandemic, but for now, prices on shares and in turn dividends remain unaffected, which provides shareholders with assurance that they will have a strong buy-in on NASDAQ.

Healthcare

Drug Manufacturers—General

Biological Product (except Diagnostic) Manufacturing

1. Navigate to the AvaTrade website and select ‘Register’
2. Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
3. As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
4. Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
5. From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘AMGN’ to buy/purchase shares.
6. Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application.

Buying shares has never been this convenient and easy. #myfirstshare

View more global shares for sale – here.

• Leverage of up to 1:20
• Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
• Indices, stocks, and commodities can all be traded form a single screen.
• Client support is presented live in a multitude of languages.
• Traders have exclusive access to a variety of educational tools
• Trades can be executed across multiple platforms

More shares that can be purchased / traded through AvATrade, can be viewed here.

• Can I buy Amgen Inc shares in South Africa?
  Yes, you can.

• How to buy Amgen Inc shares
  By simply opening a free account on SA Shares, or by clicking the “Buy this Share” button to get started.

• What is the current share price?
  By clicking on the link provided above, you can view the real-time Amgen Inc share price on the platform.

• Is Amgen Inc a good share to buy?
  Yes, it is. Despite the growing concerns surrounding Covid-19, Amgen Inc. is continuing manufacturing, sales and delivery of its products and it is forecasted to be one of the very few automotive companies to make a significant rebound post-Covid-19.

• Can I buy Amgen Inc CFD through SA Shares?
  Yes, you can.